Piramal Enterprises has received approval to raise up to Rs 50 crore along with an option to retain over subscription of up to Rs 700 crore, aggregating up to Rs 750 crore through the issuance of Secured, Rated, Listed, Redeemable, Principal Protected, Market Linked Non-Convertible Debentures (NCDs) on private placement basis. The Meeting of Administrative Committee (‘Committee’) of the Board of Directors held on September 23, 2022, has approved the same.
Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.
